In December 2008 the Department of Health in England published the Pharmaceutical Price Regulation Scheme. It describes how the scheme will operate for at least five years from 2009. The previous scheme was […]
If the UK’s planned distribution of a vaccine for covid-19 is to win widespread support it should be both clinically and cost effective. One dilemma is between prioritizing those at […]
NICE has come of age. At 21, it is a national treasure. But like other national treasures, from Alan Bennett to Grayson Perry, we forget how subversive and challenging they […]
Quality Adjusted Life Years (QALYs) have become common in research, partly due to being used by National Institute for Health and Care Excellence (NICE). A long running effort to update […]
The high prices charged by companies for cancer drugs has led to lots of speculation, but very little explanation. The most interesting attempt to explain these high prices has been […]
NICE’s provisional rejection of Astra Zeneca’s olaparib (Lynparza) for a genetic subset (BRCA1/2 gene mutation) of ovarian cancers has several themes which have not been commented on. One is that […]
The National Institute for Health and Care Excellence (NICE) has provisionally approved sofosbuvir (brand name Sovaldi) for the treatment of hepatitis C, a decision that has surprised some commentators given its high […]
The argument over whether the NHS should fund Bexsero, the new meningitis B vaccine from Novartis, raises a global issue about the price of the new vaccine, as well as […]
This blog reports on the third workshop held by the Department of Health on the methods being planned for value based pricing, due to start in January 2014. Previous workshops […]
This blog reports on a workshop held by the Department of Health on 28 November 2012 under Chatham House rules, that is the discussion can be reported but not attributed. […]
